Implementing Combination Treatment Cost-Effectiveness Solutions Beyond the Legal Challenges – What Else Needs to be in Place?

OBJECTIVES: A key challenge to value assessment is that a treatment combination is evaluated as a single technology, but the component treatments are priced independently. This is more difficult when the component treatments are patented and produced by different manufacturers. Manufacturers only have control over the price of their treatments and not over the overall price of the combination.

Different stakeholders have published on the issue of how to attribute value to each component. However, a vital issue is how manufacturers, who may be competitors in other indications, can discuss and share information from the attribution compliantly without breaching competition law.

Current literature shows that all stakeholders: government, HTA bodies, payers, clinicians, patients and manufacturers, agree that a fair, implementable and transactable solution needs to be found.

This poster illustrates what else may need to be in place to implement potential solutions beyond the legal challenges from the industry, HTA and payer perspective.

METHODS: We have spoken with individuals from key stakeholder groups to understand the additional needs, which are being collated into a framework document for publication.

RESULTS: We will highlight the key areas for further investigative work.

CONCLUSIONS: Current literature shows that all stakeholders: government, HTA bodies, payers, clinicians, patients and manufacturers, agree that a fair, implementable and transactable solution needs to be found. This poster will provide clarity on the next steps required.